Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Article and Video CATEGORIES
2020 MELANOMA - POSTOW - Understanding Immunotherapy Resistance Mechanisms in Melanoma
dbrock
2020 MELANOMA - Understanding Immunotherapy Resistance Mechanisms in Melanoma
Image
GRACE is excited to bring you a new series on current updates in Melanoma Treatment.
Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chief of Melanoma Service at Memorial Sloan Kettering, and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University School of Medicine in Easton, PA joined GRACE to discuss current updates in treatment for Melanoma.
In this video, Dr. Postow discusses understanding immunotherapy resistance mechanisms in melanoma.
A huge thank you to Merck for sponsoring this program.
To join the conversation, visit https://cancergrace.org/forum.
Video Language
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Image
Article
Tell your story and help us help others! Apply online now for this paid opportunity. This program gives a voice to those who have experience in participating in a clinical trial for a cancer diagnosis. Your voice helps to educate and advocate for others who are in or who may be considering a clinical trial. We want to hear from you!
Image
Video
The Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón presentado el 9 de agosto de 2025 has now ended.
¡Los vídeos están disponibles BAJO DEMANDA!
Las versiones completas sin editar del Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón de agosto de 2025 ya están disponibles BAJO DEMANDA. Estos temas se editarán y se ofrecerán en forma de vídeos más cortos en las próximas semanas.
Image
Article
Da click aquí para más información y para registrarte ahora
Online Community
Hi Stan! So good to hear from you. I'm sorry for the late response. I too have been out of town with family and missed your post, probably because I was...
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components: